Construction method of vlp vaccine presenting il-33 for active immunotherapy of chronic asthma

Abstract

The invention provides a method for constructing an IL-33 presentation VLP (Virus-Like Particle) vaccine used in active immunotherapy of chronic asthma. The method comprises the following steps: extracting IL-33 total RNA (Ribonucleic Acid) from a mouse; performing reverse transcription to obtain IL33 total cDNA (complementary deoxyribonucleic acid); performing PCR (Polymerase Chain Reaction) amplification on the obtained total cDNA with a designed specific primer to obtain a coded IL-33 mature segment gene; inserting the gene between 78-bit amino acid and 79-bit amino acid of a hepatitis B virus core antigen HBcAg to obtain a recombinant plasmid pHBcAg33; transferring the plasmid onto escherichia coli DH5alpha or a BL21 competent cell; inducing by using IPTG (isopropyl-beta-d-thiogalactoside) and purifying to obtain the IL-33 presentation VLP vaccine. A strong neutralizing antibody which is specific to own molecules and has a durable action can be induced by inoculating the vaccine repeatedly in order to regulate and control immune response, thereby fulfilling the aim of regulating and controlling the progress of asthma.

Description

technical field [0001] The invention relates to a preparation method of an anti-cytokine virus-like particle vaccine—IL-33 virus-like particle vaccine, and its therapeutic use in asthma, belonging to the field of medical biotechnology. Background technique [0002] Interleukin-33 (IL-33 for short) is a new cytokine discovered by bioinformatics technology in 2005, which belongs to the IL-1 family member. Abundantly expressed in human smooth muscle cells and bronchial epithelial cells as well as dendritic cells. The main function is to promote Th2-type immune response, and its function is that IL-33 has a strong function of stimulating Th2 differentiation and activation. By stimulating the expression of Th2 cytokines, IL-33 can promote the synthesis of IgE by B cells, promote the recruitment, maturation and survival of mast cells, and stimulate the survival and effector functions of eosinophils and basophils. [0003] Asthma is a serious airway inflammatory disease, and its ...

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to construct an effective virus-like particle vaccine that contains the whole molecule of IL-33 mature protein for the problem that existing technical means cannot effectively treat asthma. It can induce strong neutralizing antibodies against self-molecules with persistent effect to regulate the immune response, so as to achieve the purpose of regulating the disease process of asthma

Images